Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

【24h】

Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

机译：最终分析阶段1对雌激素（RAD1901）的研究，一种新颖的选择性雌激素受体降解剂（SERD），雌激素受体阳性（ER加），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：最终分析阶段1对雌激素（RAD1901）的研究，一种新颖的选择性雌激素受体降解剂（SERD），雌激素受体阳性（ER加），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌
2. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer [J] . Bardia Aditya, Kaklamani Virginia, Wilks Sharon, Journal of Clinical Oncology . 2021,第12期

机译：I阶段研究Quactrant（RAD1901），一种新颖的选择性雌激素受体降解剂，在ER阳性，HER2阴性晚期乳腺癌中
3. Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：新型选择性雄激素受体调节剂（SARM），RAD140，雌激素受体阳性（ER加），人表皮生长因子受体2阴性（HER2-），转移性乳腺癌
4. Estrogen Receptors and Selective Estrogen Receptor Modulators in Bladder Cancer [C] . Kristi Hoffman, Carolyn L. Smith ^dgt, Baylor College of Medicine, Genitourinary Cancers Symposium . 2012

机译：膀胱癌中雌激素受体和选择性雌激素受体调节剂
5. Selective utilization of ectopic epidermal growth factor receptor signaling in estrogen receptor positive breast cancer cells. [D] . Miller, David Lee. 1996

机译：雌激素受体阳性乳腺癌细胞中异位表皮生长因子受体信号的选择性利用。
6. Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3 N0–N1 Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study [O] . Maria Vittoria Dieci, Valentina Guarneri, Fable Zustovich, 2019

机译：T21–T3N0–N1雌激素受体阳性/人表皮生长受体2阴性乳腺癌的21基因乳腺癌检测对治疗决策的影响：多中心ROXANE研究的最终结果
7. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models [O] . Teeru Bihani, Hitisha K. Patel, Heike Arlt, 2017

机译：选择性雌激素受体降解剂（SERD），具有抗肿瘤活性，在多er +乳腺癌患者衍生的异种移植模型中具有抗肿瘤活性

Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

著录项

相似文献

相关主题

期刊订阅